
JNJ
Johnson & JohnsonA high-quality mega-cap income stock trading at a premium valuation. Frameworks sharply disagree on it.
Mkt Cap
$546.74B
P/E
—
PEG
2.88
P/B
6.73
Dividend
2.42%
ROE
26.4%
About the business
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Price history
Drag across the chart to select a custom period — all analysis below refocuses to that window.
What this means: A significant rerating — the valuation-sensitive frameworks below will have tightened since this move.
News & events
Next earnings
Wed, Jul 15 · consensus EPS $2.84 · last actual $2.70
Johnson & Johnson Launches Shockwave C2 Aero Coronary IVL Catheter
MT Newswires · just now
Assessing Johnson & Johnson (JNJ) Valuation After Recent Pullback And Conflicting Fair Value Signals
Simply Wall St. · just now
This 1 Insane Nvidia Stat Explains Why Wall Street Can’t Stop Buying the Stock
24/7 Wall St. · just now
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
Zacks · just now
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
Business Wire · just now
Stryker values Amplitude Vascular purchase at up to $835M
MedTech Dive · just now